Abstract
Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency because of the release of tumour cell components such as uric acid, which can lead to hyperuricemia and acute kidney injury (AKI). Objective: To analyse serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Method: This study was a prospective observational study conducted from March to July 2020. Inclusion criteria were haematological malignancies in paediatric patients with TLS and high-risk TLS who received allopurinol 10 mg/kg/day in 2-3 divided doses. Collected data were the serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Result: There were 14 sample in total during the study. There was a significant difference in uric acid level on day six after allopurinol administration compared to baseline in patients with high-risk TLS (p < 0.05). Conclusion: Allopurinol was inadequate in reducing uric acid levels in TLS patients but adequate in reducing uric acid levels in patients with high-risk TLS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
